A twice-yearly injection of Lenacapavir, however, offers a 96% lower risk of infection overall.
Clinical Trials
The rates of heart failure events and cardiovascular death were lower in the finerenone group compared with the placebo group.
Delivering a healthy copy of a gene to a person whose gene(s) are malfunctioning is known as gene therapy.
The CRISPR technology-based experimental gene editing medication EDIT-101, created by Editas Medicine, was tested for safety and efficacy in the BRILLIANCE study